文献速递骨质疏松与代谢性骨病

地舒单抗对绝经后骨质疏松症女性小梁骨评分的影响

Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
PubMed 文献 · Osteoporos Int · 2017-07-26

本研究为FREEDOM研究的回顾性分析,纳入285例绝经后骨质疏松症女性(安慰剂128例,地舒单抗157例),评估地舒单抗对小梁骨评分(TBS)的影响。结果显示地舒单抗组TBS在12、24、36个月分别较基线升高1.4%、1.9%、2.4%,且与骨密度变化基本无关。

要点

  • 地舒单抗组TBS在12、24、36个月较基线分别升高1.4%、1.9%、2.4%,与安慰剂组相比差异有统计学意义。
  • TBS变化与骨密度变化基本无关,提示地舒单抗对骨质量有独立于骨密度的影响。
  • 安慰剂组骨密度和TBS各访视点较基线变化≤0.2%或下降。

核心结论

  • 在绝经后骨质疏松症女性中,地舒单抗显著改善TBS,且该改善独立于骨密度。

研究设计与样本

  • FREEDOM研究的回顾性分析,纳入285例绝经后骨质疏松症女性(安慰剂128例,地舒单抗157例),这些女性基线及至少一次基线后访视有TBS值。
  • 受试者腰椎或全髋骨密度T值<-2.5且两部位均≥-4.0,随机接受安慰剂或地舒单抗60 mg皮下注射每6个月一次。
  • TBS指数由基线和第12、24、36个月的DXA扫描确定。

主要发现

  • 总体平均(SD)腰椎骨密度T值为-2.79(0.64),平均(SD)TBS为1.200(0.101)。
  • 安慰剂组各访视点骨密度和TBS较基线变化≤0.2%或下降。
  • 地舒单抗组第12、24、36个月骨密度较基线分别升高5.7%、7.8%、9.8%,TBS较基线分别升高1.4%、1.9%、2.4%。
  • TBS百分比变化与基线相比有统计学意义(p < 0.001),与安慰剂组相比也有统计学意义(p ≤ 0.014)。
  • 无论治疗组别,TBS与骨密度在基线或年度变化上基本无关(所有r² ≤ 0.06)。

关键数值与推荐

  • 地舒单抗组TBS较基线变化:12个月1.4%,24个月1.9%,36个月2.4%(与基线比较p < 0.001,与安慰剂比较p ≤ 0.014)。
  • 地舒单抗组骨密度较基线变化:12个月5.7%,24个月7.8%,36个月9.8%。
  • TBS与骨密度相关性:所有r² ≤ 0.06。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ray absorptiometry (DXA) scans. In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of bone mineral density (BMD). This practical technique may have a role in managing patients with osteoporosis. INTRODUCTION: TBS, a gray-level texture index determined from lumbar spine DXA scans, correlates with bone microarchitecture and enhances assessment of vertebral fracture risk independently of BMD. In the FREEDOM study, denosumab increased BMD and reduced new vertebral fractures in postmenopausal women with osteoporosis. This retrospective analysis explored the effect of denosumab on TBS and the association between TBS and BMD in FREEDOM. METHODS: Postmenopausal women with lumbar spine or total hip BMD T-score <-2.5 and -4.0 or higher at both sites received placebo or denosumab 60 mg subcutaneously every 6 months. TBS indices were determined from DXA scans at baseline and months 12, 24, and 36 in a subset of 285 women (128 placebo, 157 denosumab) who had TBS values at baseline and ≥1 postbaseline visit. RESULTS: Baseline characteristics were comparable between treatment groups; mean (SD) lumbar spine BMD T-score was -2.79 (0.64), and mean (standard deviation [SD]) TBS was 1.200 (0.101) overall. In the placebo group, BMD and TBS increased by ≤0.2% or decreased from baseline at each visit. In the denosumab group, progressive increases from baseline at 12, 24, and 36 months were observed for BMD (5.7, 7.8, and 9.8%) and TBS (1.4, 1.9, and 2.4%). Percentage changes in TBS were statistically significant compared with baseline (p < 0.001) and placebo (p ≤ 0.014). TBS was largely unrelated to BMD, regardless of treatment, either at baseline or for annual changes from baseline (all r 2 ≤ 0.06). CONCLUSIONS: In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of BMD.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. McClung MR, Lippuner K, Brandi ML, et al. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporos Int. 2017. PMID: 28748386. doi:10.1007/s00198-017-4140-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。